Viking Therapeutics Unveils Promising Results in Obesity Treatments with VK2735 Pipeline Viking Therapeutics shared significant advancements in their VK2735 drug pipeline aimed at obesity treatment. Key developments include Phase 3 trials and promising financial updates.

Viking Therapeutics Unveils Promising Results in Obesity Treatments with VK2735 Pipeline #United_States #San_Diego #Viking_Therapeutics #VK2735 #Phase_3_Trials

Trevi Therapeutics Reports Incisive Financial Results and Key Business Developments for Q3 2025 Trevi Therapeutics has announced its financial results for Q3 2025, unveiling plans for a comprehensive Phase 3 program aimed at addressing chronic cough in IPF patients.

Trevi Therapeutics Reports Incisive Financial Results and Key Business Developments for Q3 2025 #United_States #New_Haven #Trevi_Therapeutics #Haduvio #Phase_3_Trials

MoonLake Immunotherapeutics Faces Class Action Suit After Troubling Phase 3 Trial Results for Sonelokimab Following severe Phase 3 trial results for Sonelokimab, MoonLake Immunotherapeutics faces a class action lawsuit from impacted investors amid allegations of misleading information.

MoonLake Immunotherapeutics Faces Class Action Suit After Troubling Phase 3 Trial Results for Sonelokimab #Phase_3_Trials #MoonLake #sonelokimab

Hansa Biopharma Reports Significant Financial Progress in Q2 2025 Hansa Biopharma has shared its impressive interim financial results for the first half of 2025, reflecting strong sales growth and strategic advancements in their pipeline.

Hansa Biopharma Reports Significant Financial Progress in Q2 2025 #Sweden #Lund #Hansa_Biopharma #IDEFIRIX #Phase_3_Trials